RESUMEN
Studies have been carried out on the levels of serum and urine colony stimulating activity (CSA) and peripheral blood and bone marrow colony forming cell numbers in children with acute lymphocytic leukemia (ALL) during various phases of their disease. These studies have suggested that serum and urine levels of colony stimulating factor are reduced during the inital or relapse phase of the disease compared to levels found during remission. It has also been found that the number of bone marrow colony forming cells is reduced in relapse or before treatment and elevated during remission while the number of peripheral blood colony forming cells is increased during relapse or before treatment and normal during remission. It has also been shown that mixing of serum or leukemic cells with normal human bone marrow cells inhibits colony formation.
Asunto(s)
Leucemia Linfoide/diagnóstico , Adolescente , Niño , Preescolar , Factores Estimulantes de Colonias/sangre , Factores Estimulantes de Colonias/orina , Granulocitos , Hematopoyesis , Humanos , Recurrencia , Remisión EspontáneaAsunto(s)
Rabdomiosarcoma/terapia , Adolescente , Adulto , Niño , Preescolar , Ciclofosfamida/uso terapéutico , Dactinomicina/uso terapéutico , Femenino , Humanos , Lactante , Masculino , Rabdomiosarcoma/tratamiento farmacológico , Rabdomiosarcoma/radioterapia , Rabdomiosarcoma/cirugía , Vincristina/uso terapéuticoRESUMEN
A growing literature supports the concept that some cases of neuroblastoma are hereditary. To this we add the first known case, to our knowledge, of neuroblastoma in a parent and child. Various factors, such as the remarkable tendency for this tumor to regress spontaneously, as well as its frequent fatal outcome, have reduced the number of observed familial cases. It is important that siblings and progeny of patients with neuroblastoma be examined to detect possible subclinical neuroblastoma.
Asunto(s)
Regresión Neoplásica Espontánea , Neuroblastoma/genética , Neoplasias Retroperitoneales/genética , Factores de Edad , Catecolaminas/orina , Humanos , Lactante , Masculino , Neuroblastoma/orina , Neoplasias Retroperitoneales/orinaRESUMEN
The clinical and histopathological findings in 26 children with non-Hodgkin's lymphoma without initial marrow involvement are reviewed. A marked male predominance similar to that observed in previous series was noted. Biopsy material was classified according to the recommendations of Rappaport in 22 cases. All have diffuse lymphomas, and 16 of 22 patients had involvement of the mediastinum as part of their initial presentation. Of these 12, 5 developed lymphomatous involvement of the central nervous system prior to the development of leukemic transformation of the bone marrow. This observation suggests that prophylactic therapy against CNS relapse be considered for children with mediastinal non-Hodgkin's lymphoma, even in the absence of initial marrow involvement.
Asunto(s)
Enfermedades del Sistema Nervioso Central/patología , Linfoma/patología , Enfermedades del Sistema Nervioso Central/etiología , Enfermedades del Sistema Nervioso Central/prevención & control , Niño , Preescolar , Femenino , Neoplasias Gastrointestinales/patología , Humanos , Leucemia/patología , Linfoma/complicaciones , Linfoma/terapia , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/terapia , Masculino , Neoplasias del Mediastino/patología , Recurrencia Local de Neoplasia/prevención & control , Pronóstico , Factores SexualesAsunto(s)
Doxorrubicina/uso terapéutico , Neoplasias/tratamiento farmacológico , Adolescente , Factores de Edad , Niño , Femenino , Humanos , MasculinoRESUMEN
Until alternate diagnostic methods are discovered, the staging procedure seems to be the most reliable method to establish the presence or absence of abdominal involvement in Hodgkin's disease. Our experience with staging laparotomy in 22 children raises serious questions as to both the risk of operation and the prognostic value of a negative abdominal exploration. Routine use of the staging laparotomy may not be justified in clinical Stage IA patients with lymphocyte-predominant cell type. Because of the hazards and limitations of the staging procedure, vigorous attempts would seem to be indicated to identify subcategories of patients in whom the likelihood of intraabdominal involvement is so small as to negate the value of surgical staging.
Asunto(s)
Enfermedad de Hodgkin/patología , Complicaciones Posoperatorias , Esplenectomía/efectos adversos , Adolescente , Biopsia/efectos adversos , Niño , Preescolar , Encefalitis/etiología , Femenino , Fístula/etiología , Herpes Zóster/etiología , Humanos , Infarto/etiología , Obstrucción Intestinal/etiología , Intestino Delgado/irrigación sanguínea , Intususcepción/etiología , Yeyuno , Laparotomía/efectos adversos , Enfermedades Linfáticas/etiología , MasculinoAsunto(s)
Neoplasias Abdominales , Inmunidad Celular , Terapia de Inmunosupresión , Vacuna Antisarampión , Regresión Neoplásica Espontánea , Neuroblastoma , Neoplasias Abdominales/inmunología , Femenino , Neoplasias Femorales , Humanos , Terapia de Inmunosupresión/métodos , Lactante , Recurrencia Local de Neoplasia , Neuroblastoma/inmunología , Remisión EspontáneaRESUMEN
In 1970, a staging based on surgical resectability of hepatic tumors was devised. Adjuvant chemotherapy with vincristine, 5-fluorouracil, and cyclophosphamide has been given to seven recent cases. Objectives of this study were to set up unified clinical staging and followup; to evaluate the effect of combination chemotherapy on survival in advanced disease; and to evaluate early adjunctive combination chemotherapy in surgically resectable lesions to, hopefully, prevent metastasis. Results to date in seven patients are: no change in the poor prognosis of the three female patients presenting with Stage III-IV hepatocellular carcinoma; the three males with Stage I-II hepatoblastoma have done well and survive the free of disease at 47 months, 44 months, and 28 months; one patient with hepatoblastoma had lung metastasis at diagnosis and died at 7 months with tumor. No toxicity was noted with the use of adjunctive combination chemotherapy following major hepatic resection.